Dr. Hillman has successfully represented clients across a wide range of highly targeted fields, including:
- Agriculture
- Antibody therapeutics
- Bioinformatics
- Biosensors
- CAR T-cell technologies
- CRISPR technologies
- Human and veterinary diagnostics
- Fermentation technologies
- Food processing technologies
- Human and veterinary diagnostics
- Human gene therapy
- Immunotherapy
- Liposomes
- Medical devices
- Molecular biology
- Orthobiologics
- Personal diagnostics
- Personalized medicine
- Pharmaceuticals
- Proteomics
- RNA interference (RNAi)technologies
- Tissue scaffolds
Located in Boston, Dr. Hillman focuses on biotechnology and life sciences, including innovations such as mRNA, CRISPR and CAR T therapies. Her knowledge has earned her invitations to speak at prominent industry events, including ACI’s 13th Summit on Biosimilars & Innovator Biologics in Boston, where she led a workshop on leveraging IP protections for the successful commercialization of emerging biotechnologies. She has also contributed to critical discussions on patenting strategies in the biotech field, including serving as a panelist at the USPTO’s AI and Emerging Technologies Partnership Series in San Diego and at ACI’s Advanced Summit on Life Sciences Patents in New York City.
In recognition of her contributions to the intellectual property landscape, Dr. Hillman was named a “Shining Light” in World Intellectual Property Review’s 2023 listing of influential women in IP, underscoring her impact on shaping the future of IP law in the life sciences sector.